Literature DB >> 20662097

Characterization of ST2 transgenic mice with resistance to IL-33.

Hiromi Ohto-Ozaki1, Kenji Kuroiwa, Naoko Mato, Yasushi Matsuyama, Morisada Hayakawa, Hiroyuki Tamemoto, Shin-ichi Tominaga.   

Abstract

IL-33, a member of the IL-1 family, activates MAPK and NF-kappaB through its receptor ST2L and IL-1RAcP. ST2, a member of the IL-1R superfamily, is a secreted form of ST2 gene products, which has been shown to act as a decoy receptor for IL-33 and to inhibit the IL-33/ST2L/IL-1RAcP signaling pathway. In this work, we generated ST2 transgenic mice. In control mice, intraperitoneal administration of IL-33 caused an increased number of eosinophils in blood and in peritoneal cavity, an increased number of peritoneal M Phi, splenomegaly, accumulation of periodic acid-Schiff-positive material in the lung, and high concentrations of serum IL-5 and IL-13. However, these alterations were hardly detectable in ST2 Tg mice. In peritoneal M Phi from IL-33-stimulated mice, mRNA expression of M2 M Phi marker genes were increased compared with thioglycollate-elicited peritoneal M Phi. The IL-33-stimulation also increased the secretion of IL-6 from M Phi. However, when the IL-33 was preincubated with ST2 prior to its addition to the M Phi cultures, the secretion of IL-6 was attenuated. These data suggest that, though IL-33 induced the Th2-type immune responses and infiltration of M2 type M Phi into the peritoneal cavity, ST2 can downregulate these reactions both in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20662097     DOI: 10.1002/eji.200940291

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

Review 1.  Transgenic modelling of cytokine polarization in the lung.

Authors:  Charles S Dela Cruz; Min-Jong Kang; Won-Kyung Cho; Chun Geun Lee
Journal:  Immunology       Date:  2010-11-23       Impact factor: 7.397

Review 2.  Interleukin-33 and its Receptor in Pulmonary Inflammatory Diseases.

Authors:  Jing Zhao; Yutong Zhao
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

Review 3.  IL-33/ST2 axis in inflammation and immunopathology.

Authors:  Marija Milovanovic; Vladislav Volarevic; Gordana Radosavljevic; Ivan Jovanovic; Nada Pejnovic; Nebojsa Arsenijevic; Miodrag L Lukic
Journal:  Immunol Res       Date:  2012-04       Impact factor: 2.829

Review 4.  Molecular biology of atopic dermatitis.

Authors:  Zhanglei Mu; Yan Zhao; Xiaojing Liu; Christopher Chang; Jianzhong Zhang
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

5.  IL-33 promotes eosinophilia in vivo and antagonizes IL-5-dependent eosinophil hematopoiesis ex vivo.

Authors:  Kimberly D Dyer; Caroline M Percopo; Helene F Rosenberg
Journal:  Immunol Lett       Date:  2012-12-11       Impact factor: 3.685

6.  Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33.

Authors:  Geethani Bandara; Michael A Beaven; Ana Olivera; Alasdair M Gilfillan; Dean D Metcalfe
Journal:  Eur J Immunol       Date:  2015-09-09       Impact factor: 5.532

7.  ST2 deletion enhances innate and acquired immunity to murine mammary carcinoma.

Authors:  Ivan Jovanovic; Gordana Radosavljevic; Maja Mitrovic; Vanda Lisnic Juranic; Andrew N J McKenzie; Nebojsa Arsenijevic; Stipan Jonjic; Miodrag L Lukic
Journal:  Eur J Immunol       Date:  2011-07       Impact factor: 5.532

8.  Respiratory Syncytial Virus Disease Is Mediated by Age-Variable IL-33.

Authors:  Jordy Saravia; Dahui You; Bishwas Shrestha; Sridhar Jaligama; David Siefker; Greg I Lee; Jeffrey N Harding; Tamekia L Jones; Cynthia Rovnaghi; Bindiya Bagga; John P DeVincenzo; Stephania A Cormier
Journal:  PLoS Pathog       Date:  2015-10-16       Impact factor: 6.823

9.  STAT3 and ERK pathways are involved in cell growth stimulation of the ST2/IL1RL1 promoter.

Authors:  Kenji Tago; Satoshi Ohta; Megumi Funakoshi-Tago; Chihiro Aoki-Ohmura; Jitsuhiro Matsugi; Shin-Ichi Tominaga; Ken Yanagisawa
Journal:  FEBS Open Bio       Date:  2017-01-19       Impact factor: 2.693

10.  ST2 gene products critically contribute to cellular transformation caused by an oncogenic Ras mutant.

Authors:  Kenji Tago; Satoshi Ohta; Masaki Kashiwada; Megumi Funakoshi-Tago; Jitsuhiro Matsugi; Shin-Ichi Tominaga; Ken Yanagisawa
Journal:  Heliyon       Date:  2017-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.